Results: Compared with the baseline (W0), at the end of the eighth week (W8) two group without anxiety and depression, anxiety and depression in patients with mild to moderate SAS, SDS score decreased significantly, the difference MLN0128 was statistically significant (P < 0.05). Houever, severe anxiety and depression in patients with SAS, SDS score were not significantly decreased, no significant differences (P < 0.05). After the treatment, the total curative effect of patients with mild to moderate anxiety and depression in the study group were higher than those in the control group (97.32% VS 17.98%, P < 0.001). However,
no statistical significance in the two group without anxiety and depression, severe anxiety and severe depression patients with
different total curative effect (P > 0.05). Conclusion: Low dose of Flupentixol and melitracen can effectively alleviate the symptoms of FD patients, significantly improve the without anxiety and depression, mild to moderate anxiety and depression in patients with psychological score. Key Word(s): 1. functional dyspepsia; 2. deanxit; 3. anxiety; 4. depression; Presenting Author: XUE HAN Additional Authors: KUI JIANG, BANGMAO WANG, LU ZHOU, XIN CHEN, SHU LI Corresponding HM781-36B manufacturer Author: KUI JIANG Affiliations: General Hospital of Tianjin medical university Objective: To investigate the clinical effect of rebamipide in chronic gastritis patients. Methods: 180 patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with
rebamipide 0.1 g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment. click here Results: compare experimental group and control group in the differences of clinical symptoms, gastric mucosal lesions and inflammation grade scores between pre-treatment and post-treatment respectively (2.62 ± 1.86 vs. 1.55 ± 1.61, 0.57 ± 1.05 vs. 0.16 ± 0.90, 0.43 ± 0.96 vs. 0.01 ± 0.72), and the differences have statistical significance (P < 0.05). Conclusion: Rebamipide can improve clinical symptoms, gastric mucosal lesions, and pathologic grade (inflammation) of chronic gastritis safely, and hence it is and worthy of applying in clinical practice. Key Word(s): 1. Rebamipide; 2. chronic gastritis; 3. clinical effect; 4.